[Positron emission tomography/computed tomography for lung cancer staging]

Area of Science:

• Oncology
• Radiology
• Nuclear Medicine

Background:

• Positron Emission Tomography/Computed Tomography (PET/CT) is a standard imaging modality for staging lung cancer.
• Accurate staging is critical for treatment planning and prognosis in lung cancer patients.

Purpose of the Study:

• To evaluate the efficacy of PET/CT in detecting metastatic disease in lung cancer patients.
• To analyze the accuracy of PET/CT for nodal staging and identifying distant metastases.

Main Methods:

• Retrospective review of 143 lung cancer patients who underwent F18-Fluorodeoxyglucose PET/CT scans for staging.
• Calculation of Standardized Uptake Value maximum (SUVmax) for primary tumors, lymph nodes, and metastases.
• Comparison of PET/CT findings with available histological data and brain MRI.

Main Results:

• Nodal involvement was detected in 60% of patients, with skip metastases observed in 17%.
• PET/CT demonstrated high sensitivity and specificity for nodal staging with SUVmax cut-offs of 4.4 (hilum) and 4.0 (mediastinum).
• Distant metastases were identified in 46.2% of patients, commonly in bone (22%), adrenal glands (16%), and liver (14%). PET/CT also detected unexpected synchronous cancers in 6% of cases.

Conclusions:

• PET/CT is an accurate tool for nodal staging in lung cancer, with SUVmax serving as a reliable uptake index.
• Distant metastases are frequently detected by PET/CT, highlighting the importance of this modality for comprehensive staging.